Evelo

Click here to read our Frontiers in Immunology paper on the small intestinal axis

Evelo

Inflammatory Diseases

Home/Our Pipeline/Inflammatory Diseases

Responding to the Worldwide Inflammation Crisis

Inflammation is a core driver of most burdensome diseases. More than one billion people worldwide suffer from classic inflammatory diseases – including psoriasis, atopic dermatitis, arthritides, asthma, allergies, inflammatory bowel disease, and neuroinflammatory diseases. While each of these diseases presents differently, all are characterized by systemic inflammation, and all have a significant, negative impact on people’s lives.

> 1 billion people suffer from classic, chronic inflammatory diseases

Worldwide, psoriasis affects over 50 million people and atopic dermatitis over 200 million people. For both diseases, the vast majority of sufferers have mild or moderate disease. In the United States, roughly 93% of psoriasis sufferers and 85% of atopic dermatitis sufferers have either mild or moderate disease, with similar distributions throughout the world.

7 Important Facts About Psoriasis (PsO) and Atopic Dermatitis (AD)

The time has come for the pharma industry to explore affordable, volume-based business models that maximize the access of sufferers to medicines on a global basis. Read the following facts about PsO and AD below to discover why we’re working toward better patient access.

1. Mild PsO and AD are serious conditions

Burdensome lesions

  • Painful, cracked skin
  • Itchy and irritating
  • Often highly visible

Quality of life impacts

  • 65% of “mild” PsO sufferers report moderate – extremely high impact on daily life1
  • Mild AD sufferers report greater impact to quality of life vs. people without AD2

Psycho-social impacts

  • 34% of “mild” PsO sufferers have depression; 27% suffer sleep disturbance3
  • 50% higher risk of depression for mild-moderate AD sufferers vs. people without AD4

1 Martin G., et al., J Clin Aesthet Dermatol. 2019:12(4):13-26.  2 Chiesa Fuxench, Z., et al., J Investigative Dermatol. 2019:139:583-590.  3 Luca M, Musumeci ML,   D’Agata E, Micali G. Int J Psychiatry Clin Pract. 2020 Mar;24(1):102-104.  4 Toron, F., Neary, M.P., Smith, T.W. et al. Dermatol Ther (Heidelb) 11, 907–928 (2021).

2. PsO and AD are associated with multiple comorbidities

Psoriasis sufferers

42% suffer from psoriatic arthritis1

58% increased risk of major cardiac event2

3X increased risk of inflammatory bowel disease1

Atopic dermatitis sufferers

Up to 20% have asthma3

30% suffer from allergies4

20% increased risk of cardiovascular death5

1 Oliveira Mde F, Rocha Bde O, Duarte GV. An Bras Dermatol. 2015 Jan-Feb;90(1):9-20.  2 Addressing NCD Psoriasis and its Comorbidities – Shared Opportunities for Action.” International Federation of Psoriasis Associations and NCD Alliance. 2017.  3 Silverberg et al. J Allergy Clin Immunol; 2013;132(5):1132-1138.  4  Silverberg JI. Ann Allergy Asthma Immunol; 2019;123(2):144-151.  5 Silverwood R J, Forbes H J, Abuabara K, Ascott A, Schmidt M, Schmidt S A J et al. BMJ 2018; 361 :k1786.

3. PsO and AD are diseases of systemic inflammation

Systemic
Inflammation

PET scans of people suffering from PsO1 and AD2 confirm systemic inflammation, including in:

Heart
Liver
Joints and tendons

1 Mehta, Nehal N., et al. Archives of dermatology 147.9 (2011): 1031-1039.  2 Ungar, Benjamin, et al, The Journal of Allergy and Clinical Immunology: In Practice 8.10 (2020): 3500-3506.

4. Few sufferers with PsO or AD receive innovative therapies that address their systemic disease

Psoriasis

Less Than 8%
in the US receive injectable antibody therapies or oral systemics1-6

Atopic dermatitis

Less Than 2%
in the US receive dupilumab (no oral systemics approved)2,9

As many as 50% of PsO and AD sufferers in the US are not on any Rx treatment2,7,8

1 IQVIA and Symphony Health Data  2 Datamonitor Healthcare, accessed June 2021.  3 Armstrong A, et al., Dermatol Ther (Heidelb). 2017 Mar; 7(1).   4 IQVIA Prescription data from Analyst Report, Oct 2020.  5 DRG Epidemiology Database 2017  6 Lebwohl MG, et al., J Am Acad Dermatol. 2014 May;70(5):871-81.e1-30.  7 Silverberg JI, et al., Allergy Asthma Immunol. 2018 Dec;121(6):729-734.e4.  8 Armstrong, April W., et al. JAMA dermatology 149.10 (2013): 1180-1185.  9 Regeneron 2020 4th quarter earnings call.

5. Therapies for PsO and AD have limitations related to safety, tolerability, convenience, and price

>50% of PsO and >90% of AD sufferers are dissatisfied with current treatment options1,2

Topicals

PsO/AD

  • Steroids, calcineurin inhibitors, others
  • Not convenient
  • Low compliance
  • No systemic impact

Old-school Systemics

PsO

  • Safety concerns
  • Monitoring requirement
  • Immunosuppressant

Oral Immunosuppressant

PsO

  • Apremilast:
    • Safety and tolerability issues
    • High price

Injectable
Biologics

PsO/AD

  • Not convenient & needle fear
  • Immunosuppressant
  • High price

1 Florek, Aleksandra G., et al., Archives of dermatological research 310.4 (2018): 271-319.    2 National Eczema Association report, 2020.

6. Dermatologists highly rate safety and tolerability when selecting a treatment for PsO and AD

Psoriasis1

  1. Safety and Tolerability
  2. Efficacy
  3. Affordability
  4. Other non-efficacy or safety related attributes

Atopic dermatitis2

  1. Safety and Tolerability
  2. Efficacy
  3. Affordability
  4. Other non-efficacy or safety related attributes

1 Alcusky, M., et al. Dermatol Ther (Heidelb) 7, 463–483 (2017).  2 Okubo, Yukari, et al. Journal of Dermatological Treatment 31.8 (2020): 821-830.

7. High priced therapies for PsO and AD reach a fraction of sufferers

Traditional Pharma High-Price Model

Antibody therapies and innovative oral therapies for PsO and AD are priced high and used by a small portion of moderate – severe sufferers

New Affordable Volume-Based Model

An effective, safe, well tolerated, oral, and affordable therapy could expand the addressable patient population

Traditional Pharma High-Price Model

Antibody therapies and innovative oral therapies for PsO and AD are priced high and used by a small portion of moderate – severe sufferers

~$40-80K per person per year (US) Injected antibody and innovative oral therapies

New Affordable Volume-Based Model

An effective, safe, well tolerated, oral, and affordable therapy could expand the addressable patient population

Our Work in Psoriasis and Atopic Dermatitis

We’re working to find a better way to treat psoriasis (PsO) and atopic dermatitis (AD). Those who suffer from PsO and AD report a significant impact on their quality of life and experience a significant psycho-social burden which has been estimated to be greater than the impact of diabetes, cardiovascular disease, and even some cancers.

There is a large need across the spectrum of disease severity, and especially for mild and moderate sufferers, for an effective, safe, well-tolerated, and affordable oral medicine that resolves the systemic inflammation that is at the core of psoriasis and atopic dermatitis.

Clinical Trials

We’re testing the safety and efficacy of our product candidates EDP1815 in the treatment of PsO and AD, and EDP1867 for the treatment of AD.

Learn more about our Psoriasis clinical trial

Learn more about our Atopic Dermatitis clinical trial

 

Contact Us

We Want to Hear From You

Let’s start the conversation. For inquiries or requests for more information, reach out.

Contact us